一种评估化疗后发热性中性粒细胞减少症（FN）风险的工具，即化疗后发热性中性粒细胞减少症（FENCE）评分已开发，但尚未广泛验证。本研究旨在验证FENCE评分作为预测淋巴瘤患者化疗后粒细胞集落刺激因子（G-CSF）突破性FN的工具。这是对2020至2021年首次接受化疗的淋巴瘤成年患者进行的前瞻性观察性研究。 患者随访至下一周期化疗，以确定任何感染事件。在135名淋巴瘤患者中，有62名（50％）男性。在FENCE各参数价值用于预测G-CSF突破性感染的比较中，晚期疾病参数表现出高敏感性（92.8％），铂类化疗药物接收则表现出高特异性（95.33％）。以12分的FENCE评分作为低风险的截止点，在所有淋巴瘤患者中进行分析，结果为0.63的高AUROCC（95％CI = 0.5-0.74％；p =0.059），在DLBCL患者群中进行分析，结果为0.65的AUROCC（95％CI = 0.51-0.79％；p=0.046）。以12分为截止点，FENCE评分可以预测发生30.0％的突破性感染事件（95％CI = 17.8-47.4％）。本研究根据FENCE评分将淋巴瘤患者分为风险组，显示该工具在预测FN事件方面具有区分能力，中度和高危组患者更有可能发生。需要进行多中心研究以验证此临床风险评分。 版权所有 © 2023 Thungthong，Chamnanchanunt，Suwanban，Nakhahes，Iam-arunthai，Akrawikrai，Bunworasate和Rojnuckarin。

A tool for estimating risk of febrile neutropenia (FN) after chemotherapy, namely the FEbrile Neutropenia after ChEmotherapy (FENCE) score, has been developed but has not been widely validated. This study aimed to validate the FENCE score as a tool for predicting granulocyte colony-stimulating factor (G-CSF) breakthrough FN among patients with lymphoma who underwent chemotherapy.This was a prospective observational study of treatment-naive adult patients with lymphoma who underwent their first cycle of chemotherapy between 2020 and 2021. The patients were followed up until the next cycle of chemotherapy to identify any infection events.Among the 135 patients with lymphoma, 62 (50%) were men. In a comparison of the value of each FENCE parameter for predicting G-CSF breakthrough infection, the parameter of advanced-stage disease showed high sensitivity of 92.8%, and receipt of platinum chemotherapy showed high specificity of 95.33%. With a FENCE score of 12 as a cutoff for low risk, analysis across all patients with lymphoma resulted in a high AUROCC of 0.63 (95% CI = 0.5-0.74%; p = 0.059), and analysis across only patients with diffuse large B-cell lymphoma (DLBCL) resulted in an AUROCC of 0.65 (95% CI = 0.51-0.79%; p = 0.046). With a cutoff point of 12, FENCE score can predict breakthrough infection events at 30.0% (95% CI = 17.8-47.4%).This study divided patients with lymphoma into risk groups according to FENCE score, showing that this instrument has discriminatory ability in predicting FN events, these being more likely to occur in patients in the intermediate- and high-risk groups. Multicenter studies are needed to validate this clinical risk score.Copyright © 2023 Thungthong, Chamnanchanunt, Suwanban, Nakhahes, Iam-arunthai, Akrawikrai, Bunworasate and Rojnuckarin.